...
首页> 外文期刊>Toxicology Letters: An International Journal Providing a Forum for Original and Pertinent Contributions in Toxicology Research >The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice
【24h】

The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice

机译:新型C-Met抑制剂Capmatinib在小鼠中减轻二乙基硝基胺急性肝损伤

获取原文
获取原文并翻译 | 示例
           

摘要

The receptor tyrosine kinase mesenchymal-epithelial transition factor (c-Met) sits at the interface between controlled cellular division of organogenesis and uncontrolled cellular division of carcinogenesis. c-Met contribution to the initial phases of liver injury and inflammation is still not resolved. Herein, we investigated the selective pharmacological intervention of c-Met by capmatinib (formerly known as INC280) in the diethylnitrosamine (DEN) acute liver injury model in mice. c-Met inhibition by capmatinib reduced DEN-induced elevation of the pro-inflammatory cytokines TNF-alpha, IL-1 beta, IL-17A, IL-23(p19/40) and IFN-gamma, which correlated well with serum markers of hepatocellular injury (ALT, AST and LDH). The protective effects possessed by capmatinib were mainly mediated by inhibiting inflammatory cells infiltration to the liver. However, hematoxylin-eosin and bax-immunohistochemical stainings revealed that capmatinib (at a dose of 10, but not 5 mg/ kg) aggravated DEN-induced hepatocellular ballooning and apoptosis, respectively. These effects were concordant with hepatocellular overexpression of the amino acid transporter CD98. Such capmatinib effects arised mostly from exaggerating the elevation of the mutagenic lipid peroxide 4-HNE along with MDA that enhanced DEN-induced compensatory proliferation evidenced by PCNA expression. In conclusion, inhibition of c-Met activation by capmatinib may provide protection against liver injury, but may trigger undesirable elevation of the mutagenic 4-HNE. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
机译:受体酪氨酸激酶间充质 - 上皮过渡因子(C-MET)坐在有机组织的受控细胞分裂与致癌细胞分裂之间的界面处。 C-MET对肝损伤和炎症初始阶段的贡献仍未得到解决。在此,我们研究了小鼠中己基硝基胺(DEN)急性肝损伤模型中Capmatinib(以前称为Inc280)的C-Met的选择性药理干预。 Capmatinib的C-Met抑制降低了促炎细胞因子TNF-α,IL-1β,IL-17A,IL-23(P19 / 40)和IFN-Gamma的升高,其与血清标志物相关肝细胞损伤(ALT,AST和LDH)。 Capmatinib所具有的保护作用主要是通过抑制肝脏浸润到肝脏的炎症细胞。然而,苏木精 - 曙红和Bax-免疫组织化学染色液显示Capmatinib(以10种,但不是5mg / kg)的加重分别加剧肝细胞膨胀和凋亡。这些效果与氨基酸转运蛋白CD98的肝细胞过表达相应。这种谱系的效果主要从夸大致致抗脂质过氧化物4-HNE的升高以及MDA,即增强了通过PCNA表达证明的DEN诱导的补偿性增殖。总之,Capmatinib的C-MET活化的抑制可以提供针对肝损伤的保护,但可能引发诱变4-HNE的不希望的升高。 (c)2016 Elsevier Ireland Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号